Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SACHIN AGARWAL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1386867448
CMS profile
943723
Location
COLLEGE STATION, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$287.73

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $287.73 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $146.43 1
Myriad Genetic Laboratories, Inc. $141.30 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SACHIN AGARWAL

NPI 1386867448 · CMS profile ID 943723

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

COLLEGE STATION, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386867448?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SACHIN AGARWAL, NPI 1386867448, CMS profile ID 943723. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386867448?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SACHIN AGARWAL, NPI 1386867448, CMS profile ID 943723. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386867448?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SACHIN AGARWAL, NPI 1386867448, CMS profile ID 943723, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386867448?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $287.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myriad Genetic Laboratories, Inc. $19.5412/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152526358 CMS
Myriad Genetic Laboratories, Inc. $121.7610/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152526356 CMS
Boston Scientific Corporation $146.4308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092633623 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $202.69 12
PY2020 $87.10 1
PY2021 $338.30 5
PY2022 $365.36 4
PY2023 $608.48 6
PY2024 $287.73 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $311,545.14 14
PY2019 Principal investigator $336,243.39 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $450.00 12/13/2019 Non-covered Recipient Entity
GOSHEN CENTER FOR CANCER CARE
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691499955
Principal investigator 1 Merck Sharp & Dohme Corporation $4,039.60 11/22/2019 Non-covered Recipient Entity
GOSHEN CENTER FOR CANCER CARE
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691499951
Principal investigator 1 Array BioPharma Inc. $92.70 11/14/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870139
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 11/13/2019 Non-covered Recipient Entity
GOSHEN CENTER FOR CANCER CARE
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691473638
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 11/13/2019 Non-covered Recipient Entity
GOSHEN CENTER FOR CANCER CARE
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691494285
Principal investigator 1 Array BioPharma Inc. $750.00 10/29/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870137
Principal investigator 1 Merck Sharp & Dohme Corporation $3,683.20 10/25/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Phase I,II Study to Assess the Safety and Efficacy of MK-3475 in Combination withTrametinib and Dabrafenib in Subjects with Advanced Melanoma No dispute reported 06/30/2026 691483309
Principal investigator 1 Gilead Sciences, Inc. $949.00 10/14/2019 Non-covered Recipient Entity
INDIANA UNIVERSITY GOSHEN CENTER FOR CANCER CARE
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676507101
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 10/11/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Phase I,II Study to Assess the Safety and Efficacy of MK-3475 in Combination withTrametinib and Dabrafenib in Subjects with Advanced Melanoma No dispute reported 06/30/2026 691483313
Principal investigator 1 Merck Sharp & Dohme Corporation $1,465.00 10/02/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691484081
Principal investigator 1 Merck Sharp & Dohme Corporation $7,496.00 09/27/2019 Non-covered Recipient Entity
GOSHEN GENERAL HOSPITAL
A Phase I,II Study to Assess the Safety and Efficacy of MK-3475 in Combination withTrametinib and Dabrafenib in Subjects with Advanced Melanoma No dispute reported 06/30/2026 691400617
Principal investigator 1 Merck Sharp & Dohme Corporation $5,877.60 09/25/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691400623
Principal investigator 1 Radius Health, Inc. $4,500.00 09/17/2019 Non-covered Recipient Entity
INDIANA UNIVERSITY HEALTH GOSHEN CENTER FOR CANCER CARE
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ERHER2- BREAST CANCER No dispute reported 06/30/2026 681772843
Principal investigator 1 Gilead Sciences, Inc. $4,032.00 09/09/2019 Non-covered Recipient Entity
INDIANA UNIVERSITY GOSHEN CENTER FOR CANCER CARE
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676507095
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 08/16/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691400619
Principal investigator 1 Merck Sharp & Dohme Corporation $5,388.40 08/16/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691418707
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/08/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691400613
Principal investigator 1 Array BioPharma Inc. $945.00 08/01/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870131
Principal investigator 1 Array BioPharma Inc. $4,550.00 08/01/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870133
Principal investigator 1 Array BioPharma Inc. $1,354.50 08/01/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870135
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 07/24/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691401197
Principal investigator 1 Array BioPharma Inc. $1,341.00 07/05/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870127
Principal investigator 1 Array BioPharma Inc. $150.00 07/05/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870129
Principal investigator 1 Novartis Pharmaceuticals Corporation $215,037.85 07/01/2019 Non-covered Recipient Entity
INDIANA UNIVERSITY HEALTH GOSHEN CENTER FOR CANCER
AN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HR HER2 NEGATIVE HER2 ADVANCED BREAST CANCER ABC WHO RECEIVED NO PRIOR HORMONAL THERAPY No dispute reported 06/30/2026 640717677
Principal investigator 1 Merck Sharp & Dohme Corporation $4,746.40 06/28/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691348031
Principal investigator 1 Merck Sharp & Dohme Corporation $5,093.20 06/28/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691348561
Principal investigator 1 Merck Sharp & Dohme Corporation $5,502.40 06/28/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691348637
Principal investigator 1 Merck Sharp & Dohme Corporation $6,676.80 06/28/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691348641
Principal investigator 1 Merck Sharp & Dohme Corporation $7,082.40 06/28/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691348645
Principal investigator 1 Array BioPharma Inc. $4,009.00 06/25/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870179
Principal investigator 1 Gilead Sciences, Inc. $41.00 02/20/2019 Non-covered Recipient Entity
INDIANA UNIVERSITY GOSHEN CENTER FOR CANCER CARE
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676507093
Principal investigator 1 Array BioPharma Inc. $1,948.50 02/01/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870125
Principal investigator 1 Array BioPharma Inc. $6,705.00 01/03/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870117
Principal investigator 1 Array BioPharma Inc. $2,625.00 01/03/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870119
Principal investigator 1 Array BioPharma Inc. $1,000.00 01/03/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870121
Principal investigator 1 Array BioPharma Inc. $5,893.00 01/03/2019 Non-covered Recipient Entity
CENTER FOR CANCER CARE AT DBA INDIANA UNIVERSITY HEALTH
A 2-Part Phase III Randomized, Open Label, Multicenter Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma No dispute reported 06/30/2026 704870123